Drug Watch

Latest News

Jasper Investigates Drug Lot Issue in CSU Study
Jasper Investigates Drug Lot Issue in CSU Study

July 8th 2025

Jasper Therapeutics reveals promising results from briquilimab trials for chronic spontaneous urticaria, showcasing strong efficacy and safety despite manufacturing challenges.

VYNE Unblinds Early VYN202 Data After Safety Pause
VYNE Unblinds Early VYN202 Data After Safety Pause

July 7th 2025

New Research Highlights Zabalafin Hydrogel's Novel Multitargeted Approach to AD Treatment
New Research Highlights Zabalafin Hydrogel's Novel Multitargeted Approach to AD Treatment

July 2nd 2025

FDA Grants Rare Pediatric Disease Designation to QRX003 for Netherton Syndrome
FDA Grants Rare Pediatric Disease Designation to QRX003 for Netherton Syndrome

June 27th 2025

REZOLVE-AD Trial Results Show Promise for Rezpegaldesleukin in Atopic Dermatitis
REZOLVE-AD Trial Results Show Promise for Rezpegaldesleukin in Atopic Dermatitis

June 27th 2025

Video Interviews
Podcasts
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
The Cutaneous Connection

More News

© 2025 MJH Life Sciences

All rights reserved.